Mylan Specialty has begun offering EpiPen, the landmark autoinjector that treats severe allegoric reactions, with no co-pay to mark the 25th anniversary of the product’s approval by the Food and Drug Administration.
Mylan Specialty, the Bernards-based specialty pharmaceutical business of Mylan Inc., is providing this co-pay card to cash-paying and commercially insured patients through Dec. 31. A coupon also is available to patients through physicians across the country.
“Mylan has a long-standing dedication to increasing awareness and preparedness for anaphylaxis and enhancing access to epinephrine auto-injectors through innovative access solutions, and the 25th anniversary campaign is part of those efforts,” Tony Mauro, president of Mylan North America, said in an e-mailed message.
The first-of-its-kind epinephrine autoinjector was developed for emergency treatment for severe allergic reactions, or anaphylaxis. Symptoms can include redness of skin, tightness of throat, nausea, dizziness and breathing problems. The company says such reactions can be caused by allergens, exercise, or unknown triggers.
The co-pay card can be downloaded online at epipen.com, which contains additional information about the product. Certain restrictions apply to the offer.
Mylan, which markets and distributes EpiPen, manufactured by Pfizer subsidiary Meridian Medical Technologies Inc., says the product is the No. 1 prescribed epinephrine autoinjector, with more than 46 million injectors dispensed since its inception.
Mylan is unveiling additional initiatives this year to mark the milestone, including plans that allow schools to obtain autoinjectors at no cost.
“We recognize that with the increase in food allergies, that the risk of anaphylaxis may be on the rise, and as the leading marketers of epinephrine autoinjectors for 25 years, we will continue to introduce educational efforts that lead to greater anaphylaxis awareness and preparedness,” Mylan CEO Heather Bresch said in a statement.
As part of efforts to introduce new programs, Mylan said it will partner with the Asthma and Allergy Foundation of America, Food Allergy Research and Education, and other advocacy organizations.
“For 25 years, the EpiPen Auto-Injector has helped people with potentially life-threatening allergies be better prepared for an anaphylactic reaction, whether they are going out to dinner, heading off for the first day of school or traveling to a foreign destination,” AAFA CEO Bill McLin said in a statement.